BioCentury
ARTICLE | Financial News

Synthorx proposes $100M IPO ahead of synthetic IL-2 clinical testing

November 16, 2018 5:43 PM UTC

Synthetic biology company Synthorx Inc. (La Jolla, Calif.) proposed to raise $100 million in a NASDAQ IPO, according to an SEC filing from Nov. 13.

Synthorx is using synthetic biology to develop a pipeline of Synthorin cytokines. Synthorins contain unnatural amino acid sequences and are engineered to have extended half-lives and increased receptor specificity (see "Base Instincts")...

BCIQ Company Profiles

Synthorx Inc.

BCIQ Target Profiles

Interleukin-2 (IL-2)